As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) has announced a revised operating plan as it evaluates a range of ...

Genevant Sciences and Arbutus Biopharma have filed five international lawsuits against Moderna Inc. to enforce patents related to their lipid nanoparticle (LNP) technology, which is used in ...

Cell therapy and oncology–focused Carisma Therapeutics started layoffs late last year. Now the company plans to wind down ...

Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced its financial results for the fourth quarter and fiscal year 2024, ...

Moderna recently faced significant legal challenges with five international lawsuits from Genevant Sciences and Arbutus Biopharma targeting its LNP technology used in products like Spikevax®.

additional Moderna products that Moderna has represented use the same LNP technology, including mRESVIA ®. Where permitted to do so at this stage, Genevant and Arbutus submitted evidence from ...

The Company, together with Genevant, is seeking fair compensation for Moderna’s and Pfizer/BioNTech’s use of Arbutus’s patented LNP technology that was developed with great effort and at a ...